癌症患者中心静脉导管相关静脉血栓栓塞:从病理生理到血栓预防及未来研究方向
综述指出癌症患者症状性导管相关血栓(CRT)发生率为4%-8%,超声或Doppler检出CRT平均发生率12%-14%,阴性预测值约95%。Meta分析显示维生素K拮抗剂或低分子肝素可使无症状及症状性CRT发生率降低约55%-60%且不增加大出血风险,但需在置管前以预防剂量启动并后续以亚治疗剂量维持。目前尚无 validated 血栓预防方案,亦未识别高危人群。
要点
- 症状性CRT发生率4%-8%,超声/Doppler检出率12%-14%,阴性预测值约95%。
- 多数CRT发生于置管后第一周内,几乎全部在第一个月内。
- VKA或LMWH预防可降低CRT发生率约55%-60%,不增加大出血风险。
核心结论
- 癌症患者CRT常见且后果显著,但迄今尚无 validated 血栓预防方案。
- VKA或LMWH在置管前以预防剂量启动并后续亚治疗剂量维持可有效减少CRT。
- 尚未识别CRT高危人群,需基于病理生理与流行病学数据探索新预防策略。
研究设计与样本
- 综述,聚焦癌症患者中心静脉导管相关静脉血栓栓塞的病理生理、流行病学与临床支持数据。
主要发现
- 症状性CRT发生于4%-8%的癌症患者。
- 超声或Doppler检出CRT平均发生率12%-14%,阴性预测值约95%。
- CRT多发生于置管后第一周内,几乎全部在第一个月内。
- Meta分析显示VKA或LMWH使无症状及症状性CRT发生率降低约55%-60%,未增加大出血风险。
关键数值与推荐
- 药理预防仅在置管前以预防剂量启动并后续以亚治疗剂量维持时有效。
临床怎么用
- 置管前启动预防剂量VKA或LMWH并后续亚治疗剂量维持可降低CRT风险。
- 超声或Doppler阴性预测值约95%,可安全排除后续症状性及无症状CRT。
局限性
- 尚无 validated 血栓预防方案。
- 尚未识别CRT高危人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Symptomatic catheter related thrombosis (CRT) occurs in 4%-8% of cancer patients. The mean incidence of CRT, detected either by echography or Doppler ranges between 12 and 14% with a high negative predictive value of about 95%, allowing the subsequent occurrence of CRT (symptomatic and asymptomatic) to be safely excluded. Despite its frequency and its medico-economic consequences, no thromboprophylaxis has been validated to date. In most patients, CRT occurs immediately after catheter insertion, most often within the first week and almost all within the first month after insertion. Meta analyses show a reduction of asymptomatic and symptomatic CRT incidence by about 55%-60% using either vitamin K antagonists or low molecular weight heparins without an increased risk of major bleeding. This pharmacological prophylaxis is only effective when started before the central venous catheter insertion at prophylactic doses and thereafter continued at subtherapeutic doses. Since no population at high risk of CRT has been identified, this review focuses on pathophysiology, epidemiology and clinical supportive data that could lead to a new CRT prophylaxis strategy.
引用
- Debourdeau P, Lamblin A, Debourdeau T, et al. Venous thromboembolism associated with central venous catheters in patients with cancer: From pathophysiology to thromboprophylaxis, areas for future studies. J Thromb Haemost. 2021. PMID: 34363736. doi:10.1111/jth.15487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。